{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:42:18Z","timestamp":1793900538492,"version":"4.8.0"},"reference-count":37,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Since Ludwig proposed the term \u201cnonalcoholic steatohepatitis\u201d (NASH) for this liver disease in 1980, there have been many advances in understanding it, including its epidemiology, pathogenesis, diagnostic methods, and treatment.  Objective: This literature review aims to discuss the most relevant aspects of metabolic dysfunction-associated steatotic liver disease (MASLD).  Methods: The review included clinical studies from the following databases: Embase, PubMed, Scopus, Web of Science, Lilacs, Ovid, and Scopus.  Results: MASLD is the most frequent liver disease worldwide, with increasing prevalence and incidence, and can evolve with liver cirrhosis and hepatocellular carcinoma. The diagnosis involves specific diagnostic criteria involving the presence of hepatic steatosis and other metabolic factors. Drug treatment, still in its incipient, involves pioglitazone, glucagon-like peptide-1 (GLP1) agonists, and sodium glucose cotransporter-2 (SGLT2) inhibitors, especially in diabetic patients. More recently, the Food and Drug Administration (FDA) approved Resmetiron for selected cases.  Conclusion: MASLD is extremely common, presents complex pathophysiology, and requires an intensive multidisciplinary approach. It is hoped that future studies will provide effective and accessible pharmacological therapeutic options for the disease. It is necessary to bring the population\u2019s attention to this condition, which can be associated with significant morbidity and mortality.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612025-117","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:05:42Z","timestamp":1757084742000},"source":"Crossref","is-referenced-by-count":3,"title":["METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE"],"prefix":"10.1590","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-220X","authenticated-orcid":false,"given":"Maria Gabriela Fernandes","family":"DEZAN","sequence":"first","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil; Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil; Universidade Federal da Bahia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-417X","authenticated-orcid":false,"given":"Claudia Pinto","family":"OLIVEIRA","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7698-6919","authenticated-orcid":false,"given":"Helma Pinchemel","family":"COTRIM","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil; Universidade Federal da Bahia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AALSD Practice Guideline on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3390\/diagnostics13193104","article-title":"From Nonalcoholic Steatohepatitis to Steatotic Liver Disease: A Long Way","volume":"13","author":"Cotrim HP","year":"2023","journal-title":"Diagnostics"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao L","year":"2024","journal-title":"Trends Endocrinol Metabol"},{"key":"ref7","first-page":"1404","article-title":"Geographical similarity and diferences in the burden and genetic predisposition of NAFLD","volume":"77","author":"Yip TCF","year":"2022","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"22","author":"Kalligeros M","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans","volume":"14","author":"Kanwal F","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2022","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek J","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cld.2023.01.004","article-title":"Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers","volume":"27","author":"Ibrahim MK","year":"2023","journal-title":"Clin Liver Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s11695-010-0212-1","article-title":"Nonalcoholic Fatty Liver Disease Associated with Obstructive Sleep Apnea: Just a Coincidence?","volume":"20","author":"Daltro C","year":"2010","journal-title":"Obes Surg"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.aohep.2023.101122","article-title":"Nonalcoholic fatty liver disease: A risk factor for chronic kidney disease","volume":"28","author":"Carvalho KD","year":"2023","journal-title":"Annals of Hepatology"},{"key":"ref15","first-page":"540","article-title":"Risk factors for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease","volume":"59","author":"Cavalcante LN","year":"2022","journal-title":"Arq Gastroenterol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2022.03.010","article-title":"Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States","volume":"21","author":"Karim MA","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review","volume":"158","author":"Loomba R","year":"2020","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.bbrc.2014.03.078","article-title":"Adipo-nutrin: a multimeric plasma protein","volume":"446","author":"Winberg ME","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.aohep.2018.10.004","article-title":"Validation of PNPLA3 polymorphisms as risk factor for NA- FLD and liver fibrosis in an admixed population","volume":"18","author":"Mazo DF","year":"2019","journal-title":"Ann Hepatol"},{"key":"ref20","first-page":"1285","article-title":"High prevalence of PNPLA3 rs738409 (I148M) polymorphism in Chilean Latino population and its association to nonalcoholic fatty liver disease risk and histological disease severity","volume":"62","author":"Arrese M","year":"2015","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/genes12050628","article-title":"The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease","volume":"12","author":"Seko Y","year":"2021","journal-title":"Genes"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1159\/000324281","article-title":"Gut-Liver Axis and Sensing Microbes","volume":"28","author":"Szabo G","year":"2011","journal-title":"Dig Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review","volume":"163","author":"Long MT","year":"2022","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.14309\/ajg.0000000000001054","article-title":"Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients with Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations","volume":"116","author":"Younossi ZM","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.14309\/ajg.0000000000001337","article-title":"Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis","volume":"116","author":"Castellana M","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepat"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aohep.2021.100341","article-title":"Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases","volume":"22","author":"Cardoso AC","year":"2021","journal-title":"Ann Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CLD.0000000000000126","article-title":"Endo-bariatric therapies as a treatment strategy for MASLD","volume":"23","author":"Gudur A","year":"2024","journal-title":"Clin Liver Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison SA","year":"2024","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20945\/2359-4292-2023-0123","article-title":"Brazilian evidence-based guidelines for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)","volume":"67","author":"Moreira RO","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort R","year":"2006","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay MS","year":"2018","journal-title":"Diabetes Care"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku A","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Doen\u00e7a hep\u00e1tica esteat\u00f3tica associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica: revis\u00e3o de literatura"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032025000101101&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:05:46Z","timestamp":1757084746000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032025000101101&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":37,"alternative-id":["S0004-28032025000101101"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612025-117","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e24117"}}